Business · 05/04/2017
FDA Clears CEDAX Oral Suspension for Approval
The FDA has determined that CEDAX oral suspension, 90mg/5mL and 180mg/5mL, were not withdrawn from sale due to safety or effectiveness concerns, paving the way for potential approval of abbreviated new drug applications.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →